The significance of GATA3 expression in breast cancer: a 10-year follow-up study

Ciocca, Vincenzo; Daskalakis, Constantine; Ciocca, Robin M.; Ruiz-Orrico, Alejandra; Palazzo, Juan

doi:10.1016/j.humpath.2008.09.010

Cited by 67 publications

(53 citation statements)

References 19 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been found that positive GATA-3 expression is among the best predictors of ER-positive status, and that low GATA-3 protein expression is an independent predictor of tumor recurrence after treatment. 65,66 GATA-3 expression was also strongly correlated with the luminal A subtype of mammary carcinomas. 65 However, it appears that GATA-3 may not be a downstream target of ER, and the GATA-3 and ER pathways may have nonoverlapping functions in mammary luminal cells.…”

Section: Discussionmentioning

confidence: 88%

A study of immunohistochemical differential expression in pulmonary and mammary carcinomas

2010

View full text Add to dashboard Cite

The risk of developing a second primary cancer is increased in patients with breast cancer, and the lung is one of the major sites involved. Moreover, the lung is the major metastatic site for breast cancers. A distinction between metastatic breast cancer and primary lung cancer can be histologically difficult, and both show an overlapping CK7 þ /CK20À immunoprofile in a majority of cases. The degree of difficulty increases with poorly differentiated tumors. We investigated differential expressions of TTF-1, Napsin A, surfactant apoprotein A, estrogen receptor, GATA-3, mammaglobin, and GCDFP-15 immunostains in 197 pulmonary carcinomas (158 adenocarcinomas, 39 squamous) and 115 invasive mammary carcinomas (91 ductal, 24 lobular type). In mammary carcinomas, estrogen receptor, GATA-3, mammaglobin, and GCDFP-15 were expressed in 74, 72, 64, and 62%, respectively, whereas TTF-1, Napsin A, and surfactant apoprotein A were all negative. The expressions were diffuse in estrogen receptor and GATA-3, and variable in mammaglobin and GCDFP-15. For a combination of estrogen receptor/mammaglobin or GATA-3/mammaglobin, 83% of mammary carcinomas were positive, and the detection rate was not improved by using all three markers. All lung squamous cell carcinomas were negative for all markers studied. TTF-1, Napsin A, and surfactant apoprotein A were positive in 80, 77, and 45% of pulmonary adenocarcinomas. None of the TTF-1-negative tumors expressed surfactant apoprotein A. GCDFP-15 was focally expressed in 2.5% of pulmonary adenocarcinomas, and estrogen receptor was focally expressed in one case (1.2%) of pulmonary adenocarcinoma. When metastasis from breast cancer is suspected in the lung, a combination of either estrogen receptor/mammaglobin or GATA-3/mammaglobin as breast markers, and a combination of TTF-1 and Napsin A as lung markers may be helpful for differentiating between the two. Caution should be taken in the interpretation of GCDFP-15 due to its occasional expression in pulmonary adenocarcinomas.

show abstract

Section: Discussionmentioning

confidence: 88%

A study of immunohistochemical differential expression in pulmonary and mammary carcinomas

2010

View full text Add to dashboard Cite

show abstract

“…69,70 Low GATA3 expression has also been suggested to correlate with poor prognosis in breast cancer. [187][188][189][190] In our recent immunohistochemical evaluation 191 of GATA3 expression in 1110…”

Section: Review Of Selected Antibodiesmentioning

confidence: 99%

Immunohistochemistry in Undifferentiated Neoplasm/Tumor of Uncertain Origin

Lin

Liu

2014

Archives of Pathology &Amp; Laboratory Medicine

106

View full text Add to dashboard Cite

Context Immunohistochemistry has become an indispensable ancillary study in the identification and classification of undifferentiated neoplasms/tumors of uncertain origin. The diagnostic accuracy has significantly improved because of the continuous discoveries of tissue-specific biomarkers and the development of effective immunohistochemical panels. Objectives To identify and classify undifferentiated neoplasms/tumors of uncertain origin by immunohistochemistry. Data Sources Literature review and authors' research data and personal practice experience were used. Conclusions To better guide therapeutic decisions and predict prognostic outcomes, it is crucial to differentiate the specific lineage of an undifferentiated neoplasm. Application of appropriate immunohistochemical panels enables the accurate classification of most undifferentiated neoplasms. Knowing the utilities and pitfalls of each tissue-specific biomarker is essential for avoiding potential diagnostic errors because an absolutely tissue-specific biomarker is exceptionally rare. We review frequently used tissue-specific biomarkers, provide effective panels, and recommend diagnostic algorithms as a standard approach to undifferentiated neoplasms.

show abstract

“…[7][8][9] In patients with breast cancer, the expression of GATA3 is closely related to estrogen receptor (ER) status, and significantly associated with a favorable prognosis. [10][11][12][13] GATA3 is the third most frequently mutated gene in breast cancer, with a mutation rate of approximately 10%. It is interesting to note that these mutations are observed for the most part in ER-positive tumors, suggesting the involvement of GATA3 mutations in the pathogenesis of luminal-like breast cancer.…”

Section: Introductionmentioning

confidence: 99%

GATA3 mutations define a unique subtype of luminal‐like breast cancer with improved survival

Jiang

Zuo

et al. 2014

Cancer

View full text Add to dashboard Cite

BACKGROUND:The GATA3 gene (GATA-binding protein 3) is one of the most frequently mutated genes in breast cancer. The objective of the current study was to determine the clinicopathologic characteristics of patients with breast cancer harboring GATA3 mutations. METHODS: The authors examined the somatic mutation status of GATA3 and performed survival analysis in The Cancer Genome Atlas (TCGA) cohort (n 5 934) and the Fudan University Shanghai Cancer Center (FUSCC) cohort (n 5 308). Patient characteristics, including age; menopausal status; tumor laterality; tumor size; lymph node status; tumor grade; molecular subtypes; adjuvant radiotherapy, chemotherapy, and endocrine therapy; and prognosis, together with PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) and TP53 (tumor protein p53) mutation status, were collected. RESULTS: GATA3 mutations were detected in 8.8% of patients (82 of 934 patients) in the TCGA cohort and 14.9% of patients (46 of 308 patients) in the FUSCC cohort. GATA3 mutations were found to be significantly associated with luminal-like breast cancer (P 5.002 in the TCGA cohort and P <.001 in the FUSCC cohort), and were highly mutually exclusive to PIK3CA mutations (P 5.001 in the TCGA cohort and P 5.003 in the FUSCC cohort) and TP53 mutations (P <.001 in both cohorts). Furthermore, GATA3 mutations were correlated with improved overall survival in the entire population (P 5.025 in the TCGA cohort and P 5.043 in the FUSCC cohort) as well as in patients with luminal-like disease who received adjuvant endocrine therapy. CONCLUSIONS: GATA3 mutations mainly occur in patients with luminal-like breast cancer and have identifiable clinicopathologic and genetic characteristics, highlighting a subgroup of patients with breast cancer in whom limited therapy may be appropriate.

show abstract

The significance of GATA3 expression in breast cancer: a 10-year follow-up study

Cited by 67 publications

References 19 publications

A study of immunohistochemical differential expression in pulmonary and mammary carcinomas

A study of immunohistochemical differential expression in pulmonary and mammary carcinomas

Immunohistochemistry in Undifferentiated Neoplasm/Tumor of Uncertain Origin

GATA3 mutations define a unique subtype of luminal‐like breast cancer with improved survival

Contact Info

Product

Resources

About